© Drug Hunter Inc. 2018-2023
Home > M3814
DNA-PK-selective kinase inhibitor
oral efficacy in xenograft radiation models
undisclosed screening and optimization
Mol. Cancer Ther., Mar. 27, 2020
Merck KGaA, Darmstadt, DE
M3814 (Merck KGaA oral DNA-PK selective kinase inhibitor)
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.
Molecules of the Month
Molecule of the Year